Shanghai Medical Team Discovers Potential Thalassemia Cure with Gene Therapy

Select Language:

A team of medical specialists in Shanghai has demonstrated that gene-editing technology can effectively treat thalassemia, a hereditary blood disorder, potentially providing patients with a one-time cure. Led by Zhai Xiaowen, deputy director of the Children’s Hospital at Fudan University, and Professor Chen Jia from ShanghaiTech University, the team successfully treated multiple children with the condition using gene therapy over the past two years.

Unlike anemia caused primarily by poor nutrition or blood loss, thalassemia results from a genetic mutation that disrupts hemoglobin production, leading to anemia. In China, more than 30 million people carry the thalassemia gene, primarily in Guangdong, Hainan, and the Guangxi Zhuang Autonomous Region, with tens of thousands suffering from severe forms of the disease.

Severe thalassemia can be life-threatening, according to Zhai. Patients require lifelong regular blood transfusions, and delays in transfusion can lead to tissue hypoxia, heart failure, or damage to multiple organs.

Traditional treatment for severe cases often involves allogeneic stem cell transplants, which are complicated by challenges in matching donors, high surgical risks, and the chance of rejection after surgery. In contrast, gene therapy involves collecting a patient’s own stem cells, editing them in the laboratory, and reinfusing them, significantly reducing surgical risks and eliminating the need for donor matches.

“From our cases so far, we’ve observed a notable decrease in transfusion frequency following treatment, with some patients no longer needing transfusions,” Zhai explained. “This has greatly enhanced their quality of life and confirms that gene editing technology can serve as a one-time curative solution.”

To move closer to achieving a permanent cure, the team plans to conduct a 15-year follow-up study to continuously assess the safety and long-term efficacy of the therapy. They also aim to offer free treatment to international patients, presenting a “China solution” for global sufferers.

Zhai highlighted that gene-editing technology is scalable and could be adapted to treat other rare blood disorders beyond thalassemia. He emphasized that integrating artificial intelligence for better target site prediction and minimizing off-target effects will be crucial in advancing future research.